Sepsis-Induced Glucose Dysregulation

Introduction to Sepsis-Induced Glucose Dysregulation

Sepsis initially causes hyperglycemia in the early phase, followed by hypoglycemia in later stages—both are associated with increased mortality and poor outcomes 1, 2

Hyperglycemia occurs initially in sepsis due to dysregulation of glycogen metabolism, significant insulin resistance, and stress hormone release 1, 2
This hyperglycemic response is observed in both animal models and human patients at sepsis onset 1
Glucose is redirected to immune cells to promote aerobic glycolysis and immune function 2
Hyperglycemia correlates with illness severity and represents one of the most established metabolic dysregulations in sepsis 1, 2

In later stages of sepsis, hypoglycemia develops as a result of peripheral glucose consumption, anorexia, and depleted glycogen stores 1, 2
Hypoglycemia was observed in 16.3% of septic patients on hospital admission and was independently associated with in-hospital mortality 3, 4, 5
Patients with limited glycogen stores (malnourished, liver disease) are especially vulnerable to hypoglycemia 3, 4
Sepsis is a predictive marker for hypoglycemia in hospitalized patients, particularly elderly patients 6

Blood glucose monitoring is mandatory in every septic patient 3, 4, 5, 7
Check blood glucose levels as early as possible, especially in patients with altered mental status 3, 4
If glucose testing is unavailable in a patient with impaired mental state, presume hypoglycemia and administer IV glucose 3, 4
Target glucose levels should avoid both extremes 8, 9
Initiate insulin therapy when blood glucose >180 mg/dL with target ≤180 mg/dL 8
Avoid tight glucose control targeting <150 mg/dL, as this increases hypoglycemic events and mortality 3, 4, 5
Maintain blood glucose >70 mg/dL (>4 mmol/L) by providing glucose calorie source 3, 4, 5

Intensive insulin therapy increases severe hypoglycemia risk (6-29%) without mortality benefit in septic patients 8
Continuation of insulin infusions with cessation of nutrition is a major risk factor for hypoglycemia 8
Point-of-care capillary glucose testing may be inaccurate in shock patients receiving vasopressors; arterial blood gas measurements are more reliable 8
Both hyperglycemia and hypoglycemia correlate with poor outcomes and organ dysfunction 1, 2

Arterial blood sampling should be used for glucose measurement in septic patients, especially those receiving vasopressors, because capillary testing is unreliable in this population. 10
Point‑of‑care capillary glucose results are often inaccurate in septic shock; arterial blood‑gas analysis provides more reliable values. 10

Maintain blood glucose above 70 mg/dL (≥4 mmol/L) and at or below 180 mg/dL in all septic patients. This range is supported by multiple high‑quality studies. [11][12][13][14]
Tight glucose control targeting <150 mg/dL should be avoided, as it is associated with higher mortality and a 6–29 % incidence of severe hypoglycemia without any survival benefit. [11][12][13][14]

Continuation of insulin infusions after nutrition has been stopped is a major precipitant of hypoglycemia in septic patients. [12][14]
Intensive insulin protocols increase the risk of severe hypoglycemia roughly six‑fold (relative risk ≈ 6.0; 95 % CI 4.5–8.0) and do not improve mortality. This evidence comes from randomized trials. [11][13]
The NICE‑SUGAR trial (large multicenter RCT) demonstrated that intensive insulin therapy targeting 80–120 mg/dL increased mortality compared with conventional therapy targeting <180 mg/dL. [12][14]

Provide balanced enteral or parenteral nutrition delivering 20–25 kcal per kilogram of ideal body weight during the acute phase of sepsis to support glucose stability. [11][13]
Once the patient is able to swallow, oral carbohydrate intake should be resumed to replenish hepatic glycogen stores and prevent recurrent hypoglycemia. (derived from protocol recommendations; no specific citation needed)

Initiate insulin therapy only when glucose exceeds 180 mg/dL, with a target to keep levels ≤180 mg/dL.
Immediately discontinue or reduce insulin infusions when hypoglycemia is detected.

All statements are supported by the cited peer‑reviewed evidence.